1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shanghai Yizhong Pharmaceutical Co. Ltd. Class A

Shanghai Yizhong Pharmaceutical Co. Ltd. Class A

SSSE:688091
36.47
CNY
-0.03
(-0.08%)
0.39EPS
102.60P/E
8.31BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.04
1.26
2.27
0.75
1.57
1.61
Basic EPS, GAAP
-0.08
-0.09
-2.26
-0.14
-0.03
0.76
1.02
0.03
0.32
0.39
Free Cash Flow per Basic Share
-0.1
-0.1
-0.51
-0.17
-0.45
0.4
0.49
-0.17
-0.74
- -
Dividend per Share
- -
- -
- -
- -
0.01
- -
0.27
0.21
- -
- -
Book Value per Share
1.28
1.38
1.72
1.58
5.71
6.41
7.12
6.8
6.92
7.21
Tangible Book Value per Share
1.22
1.32
1.66
1.52
5.67
6.37
7.08
6.76
6.78
7.07
Basic Weighted Avg Shares
130
136
140
152
114
188
158
233
202
204
Sales/Revenue/Turnover
- -
- -
- -
- -
4
236
360
174
316
328
Operating Margin (%)
- -
- -
- -
- -
-498.01
51.88
46.21
-11.39
15.81
19.64
Depreciation Expense
4
5
5
6
7
6
8
11
12
- -
Net Income, GAAP
-10
-13
-315
-22
-4
143
162
7
65
80
Effective Tax Rate (%)
- -
- -
- -
- -
- -
4.48
13.56
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-98.03
60.54
44.84
4.02
20.42
24.39
Working Capital
93
156
130
46
972
1,170
1,309
737
562
1,078
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
25
25
Total Equity
198
213
265
244
1,176
1,319
1,465
1,405
1,430
1,491
Return on Invested Capital (%)
- -
- -
- -
- -
- -
11.52
11.92
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
11.38
11.44
- -
- -
- -
Return on Common Equity (%)
- -
-6.13
-131.69
-8.59
-0.56
11.45
11.61
0.49
4.55
5.49

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
25
25
25
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
207
207
207
Market Capitalization
9,715
11,782
8,309

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
631
640
1,162
Cash, Cash Equivalents & STI
415
418
441
Accounts Receivable, Net
103
111
120
Inventories
63
51
52
Total Current Liabilities
69
68
84
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
80.75%
1.8%
Free Cash Flow
- -
-3.7%
268.17%
Net Income, GAAP
- -
-602.56%
825.49%
Sales/Revenue/Turnover
- -
- -
82.14%
Total Cash Common Dividend
- -
- -
-99.85%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
69
53
48
4
174
2025
71
89
- -
73
316
2026
79
87
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.03
- -
-0.13
0.03
2025
0.07
0.12
- -
0.07
0.32
2026
0.09
0.12
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.24
- -
- -
0.21
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jin Song Zhou
Full Time Employees
437
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.79 Renqi Road Shanghai SH China 201401
IPO Date
Sep 9, 2021
Website
yizhongpharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shanghai Yizhong Pharmaceutical Co., Ltd. focuses on the research, development, and commercialization of anti-tumor drugs and related therapeutic solutions across China. The company's primary product is injectable paclitaxel polymeric micelles, a notable chemotherapy agent that was recently integrated into the national medical insurance catalog. Shanghai Yizhong Pharmaceutical commenced its operations in 2009 and is headquartered in Shanghai, China.